IDH-mutant astrocytomas usually receive radiotherapy in conjunction with adjuvant temozolomide (TMZ), whereas glioblastomas receive radiotherapy and either concurrent or adjuvant TMZ [3]. Here, IDH2 is linked to glioblastoma.